News

The breakthrough therapy designation allows the combination therapy as a first-line treatment for people with metastatic NSCLC whose tumours have high PD-L1 expression with no EGFR or ALK

“Today’s authorization is a landmark moment in our company’s history and in the global fight against COVID-19,” said Stéphane Bancel, Chief Executive Officer of Moderna. “This is the

“This is an important milestone for ARX788 that underscores the strong unmet medical need to develop new and effective treatment options for breast cancer patients whose tumors progressed

Arvelle Therapeutics is involved in the development of advanced solutions to treat patients suffering from central nervous system (CNS) disorders. The company is currently engaged in the development

The approval has been given following the recommendation of its Subject Expert Committee (SEC). Additionally, recommendation has been made for the approval of the Phase III clinical trial

Under the terms of the proposed agreement, the company will commence distribution of the vaccine in the second quarter of 2021. The Moderna COVID-19 vaccine has not been

Expected to improve competition and access to more affordable medicines, the approval has been given to the first generic of glucagon for injection USP, 1 mg/vial packaged in

UB-612 is said to be the first multitope, synthetic peptide-based Covid-19 vaccine candidate. Under the terms of the deal, Aurobindo Pharma will leverage its existing development, commercial and

Anle138b is a disease-modifying treatment option for synucleinopathies, such as Multiple System Atrophy (MSA) and PD. The short-term Phase 1b study with PD patients will be conducted by